Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists.
MS Research Roundup: January 9, 2014
Gordon Research Conference: Myelin
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy.
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
iConquerMS™ Advances Patient-Driven Multiple Sclerosis Research
Development of oral immunomodulatory agents in the management of multiple sclerosis.
Ocrelizumab Bests Interferon in Relapsing-Remitting MS
ACTRIMS-ECTRIMS 2014 -- Day 1, morning
Immunomodulatory agents and risk of postpartum multiple sclerosis relapses.
Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis.
Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis.
LINGO-1 negatively regulates myelination by oligodendrocytes.
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
Foreseeing the Future?
Episode 63 with Dr. Helen Tremlett on studying sun exposure in MS
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement.
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis.
Roche’s ocrelizumab first investigational medicine to show efficacy in people with primary progressive multiple sclerosis in large Phase III study
ECTRIMS 2013 Day 3
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase III Studies in Multiple Sclerosis
Autoimmunity's next top models.
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

Pages